|
It was reported that the patient experienced multiple adverse events, including headache, fatigue, loss of appetite, infusion site pain, infusion site rash, adhesive tape allergy, weight loss, catheter site-related reaction, device dislodgement, wireless communication issues with the device, and overall dissatisfaction with the device.The patient began therapy with remodulin (treprostinil sodium, concentration 10.0 mg/ml) delivered via the remunity [self-filled] pump.The reported dose was 0.03125 g/kg, administered continuously via the subcutaneous (sq) route using a self-filled cassette containing 1.9 ml at a rate of 19 l per hour.
|